Date(s) - October 31,2021
9:00 am - 2:00 pm
Dr. Martha M. Rumore, Pharm D., JD, MS, LLM, FAPhA
Senior Counsel at the Manhattan law firm of Frier Levitt
Dr. Martha Rumore is a pharmacist/attorney admitted to the NY, NJ, and DC bars. She has a Pharm D. from St. John’s University, a MS in Drug Information from Long Island University, a JD from CUNY School of Law, and an LLM in Intellectual Property from the Benjamin N. Cardozo School of Law. She is currently Senior Counsel at the Manhattan law firm of Frier Levitt. Previously she was Of Counsel at the law firm of Sorell, Lenna & Schmidt, LLP and Law Offices of Albert Kit Chan in New York and a Clinical Pharmacist at Montefiore Medical Center in New York. At the law firm she focuses on pharmaceutical and medical device intellectual property including all aspects of patent law prosecution and transactional matters as well as Food, Drug & Cosmetic Law. She represents pharmacy clients in a myriad of cases ranging from change of ownership to board of pharmacy matters and PBM audits. She has 20 years of law firm experience in the area of Food, Drug & Cosmetic Law , and pharmaceutical intellectual property, especially generic pharmaceuticals. She has also worked in the pharmaceutical industry and hospital pharmacy, both at the Director level. She taught Pharmacy Law at both Long Island University and Touro College of Pharmacy for close to 20 years. In 2017, she won the Touro Faculty Research and Scholarship Award. Martha is a frequent lecturer and has over 200 publications and presentations. She is a Fellow and former Trustee of the American Pharmacists Association and in 2015 received the APhA-APPM Poster Merit Award. She is also a former member of the American Society for Pharmacy Law Board of Directors and received the 2015 Larry Simonsmeier Legal Writing Award.
ACPE # 0043-9999-21-034-L03-P and 0043-9999-21-035-L05-P
1. Examine recent legislative, legal, and regulatory changes impacting pharmacists on the federal level.
2. Review pharmacy federal laws and regulations.
3. Review recent state and Supreme court cases with widespread implications for pharmacy practice.
4. Identify trends effecting pharmacy practice in the compounding, telepharmacy, and PBM space.
5. Describe how medication errors and adverse drug events in prescribing, dispensing, administration and patient education can be prevented.
6. Understand the extent and effect of medication errors on patient health and safety.
7. Evaluate opportunities and challenges for postmarketing surveillance and adverse drug reaction notification and reporting.
8. Identify best practices to decrease potential liability from medication errors.
9. Review ISMP / FDA Medication Safety Issues 2019-2021